Filter by Category
Download the Case Study from Virginia Mason Medical Center
Learn how PIVO is impacting a major healthcare system in the United States.
News & Press
Velano Vascular Named Top Impact Company for 2021 by Real Leaders
Vascular access technology pioneer Velano Vascular was today named a Top Impact Company for 2021 by Real Leaders, the world’s first business and sustainable leadership magazine. Velano was recognized alongside such notable brands as Tesla, Beyond Meat, and Patagonia on the 2021 list for its work making hospital stays more humane and less risky for both patients and practitioners.
Four Leadership Lessons from Healthcare’s COVID-19 Response
In healthcare, the undeniable truth is that impact is measured in outcomes. Communities thrive when health systems and their mission-oriented professionals deliver positive outcomes for both health and life. The margin for error is small, so hard-won lessons become mantras upon which we build public health programs.
COVID-19 Infects Patient & Practitioner Demands, Unsettling the Future of Hospital Operations
Prior to the outbreak of COVID-19, the healthcare industry in the United States was in the midst of an intense refocusing on patient-centered care. This evolution was defined by a number of innovations, policies, and even federal reimbursement programs that prioritized emphasis on and impact to the patient experience. It led to changes in everything from the quality of hospital food, valet parking, and room amenities to fundamentally reimagined standards of care for even mundane procedures like blood draws.
Covid-19 is changing the game for health care companies and investors
Even as the health care industry has stepped up with an unprecedented response to the Covid-19 pandemic, it is being undermined by a loss of revenue, splintering of its clinical workforce, and the disintegration of normal as we know it. For health-related entrepreneurs and startups, this means the rules of engagement with their stakeholders, including venture investors, are also changing. The emergence of a new abnormal will depend on several factors.
Velano Vascular Makes Streamlined Virtual Training Tools Available to U.S. Hospitals to Aid in the COVID-19 Response
Vascular access technology pioneer Velano Vascular this past week made its new streamlined remote training program widely available for hospitals around the nation. Initially developed with existing partners utilizing its PIVO™ needle-free blood draw device in the fight against COVID-19, the platform is now available for additional hospitals and systems in need of streamlined care.
PIVO Enables Healthcare Practitioners to Obtain Blood Samples without a Needle Stick
Clinical laboratories know full well that patients do not like being stuck by needles. And hospital administrators know that increasing the hospital’s patient-satisfaction scores is important for Medicare hospital accreditation. This is why hospital administrators are devoting more attention—and budget dollars—to products that have the potential to reduce the pain experienced by patients. And patient satisfaction surveys...
New Technology Leads to Decreased Hemolysis Rates
Laboratories in an increasing number of U. S. hospitals and healthcare systems are seeing significantly lower hemolysis rates in the blood specimens their staff are collecting with new technology designed for drawing blood with a single-use, sterile device that advances into the vein through a peripheral IV (PIV). The technology, PIVO (Velano Vascular, San Francisco, California), is a needle-free blood collection device that attaches to a PIV and is used as an alternative to venipunctures...
S.F.-based startup raises $25M to expand blood collection technologies
San Francisco medical device company Velano Vascular closed a $25 million second round of financing, bringing its total overall to $50 million. The new capital will go toward expanding its needle-less blood draw device and to developing new technologies. CEO Eric Stone would not reveal what these new technologies will entail but said they will fall within the company’s mission of reducing the costs and risk of infections associated with blood draws.
